Who Paid My Doc
Mauri Carakushansky
Pediatric Endocrinology Orlando, FL Medical Doctor
NPI 1376652131 CMS profile 62794
115 Columbia St, Suite B, Orlando, FL 32806
General payments
$881
Research payments
$4,470
Ownership & investment interest
$0
Research they led as principal investigator
$371,086
Through program year 2025, Mauri Carakushansky of Orlando, FL is reported in the CMS Open Payments database as having received $881 across 57 general payments and $4,470 in research payments paid to them. Separately, studies naming them as principal investigator received $371,086 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 76th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $32 | 2 | |
| 2024 | General | $62 | 3 | |
| 2023 | General | $165 | 13 | |
| 2022 | General | $219 | 16 | |
| 2022 | Research | $3,200 | 1 | |
| 2021 | General | $17 | 1 | |
| 2021 | Research | $940 | 1 | |
| 2020 | General | $86 | 5 | |
| 2020 | Research | $330 | 1 | |
| 2019 | General | $300 | 17 |
Beside peers
- Mauri Carakushansky
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Mauri Carakushansky were reported at $32. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Mauri Carakushansky | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $300 | $196 | $68–$845 | $163 |
| 2020 | $86 | $124 | $37–$722 | $114 |
| 2021 | $17 | $134 | $35–$691 | $132 |
| 2022 | $219 | $177 | $47–$726 | $149 |
| 2023 | $165 | $236 | $75–$887 | $160 |
| 2024 | $62 | $259 | $91–$979 | $164 |
| 2025 | $32 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
60 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Florida
Joshua Yang
Pediatric Endocrinology · Orlando, FL
Henry Rodriguez
Pediatric Endocrinology · Tampa, FL
Dorothy Shulman
Pediatric Endocrinology · Tampa, FL
Michael Haller
Pediatric Endocrinology · Gainesville, FL
Alejandro Diaz
Pediatric Endocrinology · Miami, FL
Samuel Freedman
Pediatric Endocrinology · Pembroke Pines, FL
Related records
Pediatric Endocrinology in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.